Published in final edited form as:

ACS Chem Biol. 2012 November 16; 7(11): 1873–1883. doi:10.1021/cb300261e.

Manipulating JNK Signaling with (–)-zuonin A

Tamer S. Kaoud^{a,b}, Heekwang Park^h, Shreya Mitra^g, Chunli Yan^f, Chun-Chia Tseng^a, Yue Shi^f, Jiney Jose^a, Juliana M. Taliaferro^{a,b}, Kiyoun Lee^h, Pengyu Ren^f, Jiyong Hong^h, and Kevin N. Dalby^{a,b,c,d,e,*}

^aDivision of Medicinal Chemistry, The University of Texas at Austin, Austin, TX 78712

^bGraduate Programs in Pharmacy, The University of Texas at Austin, Austin, TX 78712

^cBiomedical Engineering, The University of Texas at Austin, Austin, TX 78712

^dBiochemistry, The University of Texas at Austin, Austin, TX 78712

^eTexas Institute for Drug and Diagnostic Development, The University of Texas at Austin, Austin, TX 78712

^fDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712

^gThe University of Texas MD Anderson Cancer Center, Houston, TX 77030

^hDepartment of Chemistry, Duke University, Durham, NC 27708, USA

Abstract

Recently, in a virtual screening strategy to identify new compounds targeting the D-recruitment site (DRS) of the c-Jun N-terminal kinases (JNKs) we identified the natural product (–)-zuonin A. Here we report the asymmetric synthesis of (–)-zuonin A and its enantiomer (+)-zuonin A. A kinetic analysis for the inhibition of c-Jun phosphorylation by (–)-zuonin A revealed a mechanism of partial competitive inhibition. Its binding is proposed to weaken the interaction of c-Jun to JNK by approximately 5-fold, without affecting the efficiency of phosphorylation within the complex. (–)-zuonin A inhibits the ability of both MKK4 and MKK7 to phosphorylate and activate JNK. The binding site of (–)-zuonin A is predicted by docking and molecular dynamics simulation to be located in the DRS of JNK. (+)-Zuonin A also binds JNK, but barely impedes the binding of c-Jun. (–)-zuonin A inhibits the activation of JNK, as well as the phosphorylation of c-Jun in anisomycin-treated HEK293 cells, with the inhibition of JNK activation being more pronounced. (–)-zuonin A also inhibits events associated with constitutive JNK2 activity, including c-Jun phosphorylation, basal Akt activation and MDA-MB-231 cell migration. Mutations in the predicted binding site for (–)-zuonin A can render it significantly more, or less sensitive to inhibition than wild type JNK2, allowing for the design of potential chemical genetic experiments. These studies suggest that the biological activity reported for other lignans, such as saucerneol F and zuonin B may be the result of their ability to impede protein-protein interactions within MAPK cascades.

*Correspondence should be addressed to K.N.D. kinases@me.com.

Notes: The authors declare no competing financial interest.

Supporting Information: This material is available free of charge via the Internet at <http://pubs.acs.org>.

In mammals, JNKs (c-Jun *N*-terminal kinases) are encoded by three different genes (*jnk1*, *jnk2*, and *jnk3*) that are alternatively spliced to produce a total of approximately 10 different isoforms. The predominant genes *jnk1* and *jnk2* are expressed ubiquitously, while *jnk3* is mainly expressed in neuronal tissues, the testes, and to a lesser extent in cardiac myocytes (1). As a member of the mitogen-activated protein kinase (MAPK) family, JNKs regulate various cellular functions (2). Hyperactivation of JNK occurs in a number of disease states, including type I and type II diabetes, Alzheimer's disease, arthritis, asthma, atherogenesis, heart failure and Parkinson's disease (3). Cellular stressors, including cytokines, hypoxia, UV light, and osmotic stress stimulate JNK activity, leading to pro-inflammatory, mitogenic or apoptotic signals (4), which may contribute to the oncogenic functions of JNK (5).

JNK1 plays an important role in human hepatocellular carcinoma (6) and accelerates the development of chronic colitis-induced colorectal cancer (7). Moreover, the JNK pathway is implicated in PI3K-driven human prostate cancer, where PTEN is often found inactivated, leading to increased AKT activity and elevated JNK activation, which in turn contributes to tumor cell proliferation and angiogenesis (8). However, JNK1 is also reported to act as a tumor suppressor in DMBA/TPA-induced skin tumors and in spontaneous colon cancer, highlighting the complexities of JNK signaling (9, 10). JNK2 is constitutively activated in glial tumor cell lines (11) and human glioblastoma models (12), and is implicated in the activation of Akt and over-expression of eukaryotic translation initiation factor 4 (eIF4E) (12).

Interestingly, both JNK1 and JNK2 reportedly regulate cell migration (13) and JNK2 has been shown to promote mammary cancer cell migration by specifically altering both the expression and trafficking of epidermal growth factor substrate 8 (EGFR) as well as its critical protein binding interactions, which connect growth factor signaling to the actin cytoskeleton during cell migration (14). Cell migration is an essential processes associated with tissue repair and regeneration, atherosclerosis, arthritis, mental retardation, embryonic morphogenesis and cancer metastasis (15). Recently we reported the design of peptide inhibitors that selectively targeted the protein-binding site of the JNK2 isoform and efficiently inhibit breast cancer cell migration (16). Taken together, this reveals the importance of the JNKs as attractive targets for the treatment of a variety of diseases, especially cancer. However, no inhibitors of JNK have been approved for use in humans (17).

JNKs are mainly activated by phosphorylation of the activation loop at a Thr-Pro-Tyr (TPY) motif by the MAP2Ks MKK4 and MKK7 (18) and are deactivated by MAPK phosphatases including MKP1 and MKP5. The JNK2 isoform is uniquely autophosphorylated without the requirement of MKK4 and MKK7 (19). Scaffolding proteins such as JIP (20) and arrestin (21) can assemble signaling complexes consisting of a MAP3K, a MAP2K, and a MAPK to promote specific JNKs.

Unlike ATP-competitive inhibitors, non-canonical inhibitors targeting protein interaction sites of JNK may disrupt the binding of JNK to upstream and downstream proteins, including phosphatases and scaffolds, resulting in the alteration of JNK signaling in cells. An important advantage of such non-ATP competitive inhibitors is that they do not have to

compete with an intracellular ligand that is present at high millimolar concentrations, such as ATP. In addition, inhibitors that target protein binding sites may be uniquely specific for JNK (22). Some trials have been conducted to discover small molecules targeting the protein-binding site of JNK. In 2008, Stebbins *et al.* discovered that the thiadiazole BI-78D3 (the first small molecule targeting the JNK-JIP interaction) (23) efficiently displaces biotinylated pepJIP1 from GST-JNK1 with an IC₅₀ of 500 nM. Additional reports have focused on the development of BI-78D3 and the enhancement of its plasma stability (22), while others still continue the search for different scaffolds or peptides that act as inhibitors of the JNK-protein interaction (22, 24).

The largely solvent-exposed and relatively shallow protein docking sites of JNK (25) make the discovery and design of potent non-canonical inhibitors targeting the protein binding sites of MAP kinases difficult. Recently, we attempted to overcome this challenge by employing computational studies. Using virtual screening, a group of inhibitors targeting the JNK-JIP binding site was discovered (26). One of these inhibitors, known as (–)-zuonin A (**1**, Scheme 1), selectively inhibits JNK over ERK2 and p38 MAPK. (–)-zuonin A (**1**) is a 2,5-diaryl-3,4-dimethyltetrahydrofuranoid lignan which has been isolated from *Aristolochia chilensis* (27), *Saururus cernuus* (28), *Piper schmidtii* (29), *Chamaecyparis obtusa* var. *formosana* (30), and *Piper futokadsura* (31). Notably, two recent reports have implicated other lignan derivatives as having biological effects resulting from their activity towards MAP kinases. For example, saucerneol F, a tetrahydrofuran-type sesquilignan isolated from *Saururus chinensis*, inhibits nitric oxide (NO) production in a dose-dependent manner. This effect is accompanied by reduction of the inducible nitric oxide synthase (iNOS) protein and mRNA expression in lipopolysaccharide (LPS)-stimulated murine macrophage (RAW264.7) cells. Saucerneol F was reported to attenuate NO production and iNOS expression by blocking LPS-induced activation of NF- κ B (NF-kappaB), AP-1 and most MAP kinases (including ERK1/2, p38 MAPK, and JNK) (32). Zuonin B, a stereoisomer of zuonin A, isolated from the flower buds of *Daphne genkwa*, is reported to exhibit immunological effects in RAW264.7 cells due to its ability to suppress the levels of nitric oxide, prostaglandin E2 and pro-inflammatory cytokines such as tumor necrosis factor- α and interleukin-6. The detailed study of its molecular mechanism demonstrated its ability to reduce NF- κ B activation by suppressing proteolysis of I κ B α and p65 nuclear translocation, as well as by inhibiting the phosphorylation of ERK 1/2 and JNK (33). Based on these data saucerneol F and zuonin B have been proposed to be anti-inflammatory agents. It remains to be established whether they directly bind and inhibit MAPKs.

Here we report the asymmetric synthesis of the lignans (–)-zuonin A and (+)-zuonin A and report both biochemical and biological approaches employed to show that (–)-zuonin A is an inhibitor of JNK. We identified two mechanisms as likely contributors to its ability to inhibit JNK signaling in cells.

Results and Discussion

Synthesis of (–)-zuonin A and (+)-Zuonin A

Recently, (–)-zuonin A (**1**, Scheme 1) was identified as an inhibitor of JNK following a virtual screening analysis designed to identify small molecule inhibitors of JNK-protein

interactions (26). While there are several reports of its isolation and structure determination in the literature (27-31), its synthesis has not been reported. In addition, the absolute configuration of (–)-zuonin A (**1**) has not been established. Therefore, as part of an ongoing effort to characterize bioactive lignans we embarked on the total synthesis of (–)-zuonin A (**1**), drawing on our recent synthesis of substituted tetrahydrofurans (34, 35). To this end we report a synthetic route that affords (–)-zuonin A (**1**) and its enantiomer (+)-zuonin A (**2**). As a result, the absolute configuration of (–)-zuonin A (**1**) and (+)-zuonin A (**2**) is now assigned.

Synthesis of intermediate 7—The first stages of the synthesis involve the preparation of the chiral dihydrofuranone **7** (Scheme 1) which was accomplished following previously reported procedures (34). Thus, commercially available (4*S*)-4-(1-methylethyl)-3-(1-oxopropyl)-2-oxazolidinone **3** was reacted with piperonal in the presence of *n*-Bu₂BOTf and Et₃N to provide the desired *syn*-adol adduct **4** in 78% yield as a single diastereomer (36). Protection of **4** with TBSCl (90%) followed by LiBH₄ reduction (79%) provided the corresponding alcohol **5**. Protection of **5** with MsCl and subsequent treatment with NaCN accomplished one-carbon homologation to give **6** (97% for two steps). TBS deprotection by TBAF, hydrolysis of the nitrile group to the corresponding carboxylic acid, and acid-catalyzed lactonization provided **7** in 91% for three steps.

Elaboration of 1 from 7—As demonstrated in the stereoselective synthesis of manassantins A and B, we envisioned the installation of a sterically less demanding *exo*-methylene group as a precursor to the C4 methyl group would direct the addition of **11** via the “inside attack” model to provide the desired 2,3-*cis*-2,5-*trans*-tetrahydrofuran **12** (35). Alkylation of **7** with Eschenmoser's salt and *m*-CPBA oxidation smoothly proceeded to afford **8** in 95% for two steps (37, 38). Reduction of **8** with DIBALH followed by treatment with PhSO₂H provided 2-benzenesulfonyl cyclic ether **10**. As expected, the *exo*-methylene group in **10** directed the addition of **11** to provide the desired 2,3-*cis*-2,5-*trans*-tetrahydrofuran **12** as a single diastereomer (76%). As demonstrated in the synthesis of manassantins A and B (35), catalytic hydrogenation under conventional conditions (H₂, Pd/C, EtOAc/MeOH) completed the asymmetric synthesis of **1** (38%, dr = 5:1, 97.7% ee). It should be noted that the double bond isomerization occurred during the catalytic hydrogenation reaction to give **13** (28%).

The optical rotation of **1** obtained by synthesis enabled the assignment of absolute configuration of **1**. The enantiomer (+)-zuonin A (**2**) was also prepared in a similar manner starting from the enantiomer of **3**, (4*R*)-4-(1-methylethyl)-3-(1-oxopropyl)-2-oxazolidinone.

***In vitro* studies on the mechanism of (–)-zuonin A identifies a mechanism of partial competitive inhibition**

(–)-zuonin A inhibits c-Jun phosphorylation by JNK—(–)-zuonin A was initially discovered as an inhibitor of JNK through *in silico* screening (26). We hypothesized that small molecules that bind the D-recruitment site (DRS) of JNK, a recruitment site utilized by substrates and other substrates to dock onto and recognize MAPKs (39), will block the ability of JNK to efficiently engage protein ligands. To characterize the enantiomers of

zuonin A, we first tested their ability to inhibit the phosphorylation of GST-c-Jun (2 μ M) by activated JNK1, JNK2 and JNK3. As several kinetic studies of the JNKs have been reported (40) we used these to guide the design of our kinetic investigations. First, we obtained dose-response curves for each enantiomer. (–)-zuonin A exhibits IC₅₀ values in the range of 1.7–2.9 μ M plateauing at around 75% of the theoretical maximal level of inhibition when (–)-zuonin A is saturating (Table 1 and Figure 1a). In contrast, while exhibiting similar IC₅₀ values, the level of inhibition achieved by saturating (+)-zuonin A is only 8–14% of the theoretical maximum (Figure 1b). To understand these observations further we determined the observed rate constant, k_{obs} , over a range of c-Jun concentrations at different fixed concentrations of (–)-zuonin A, in the presence of a saturating concentration of MgATP. The double reciprocal plot derived from this study (Figure 2a) is consistent with a mechanism of partial-competitive inhibition (Figure 2b, where $\alpha \sim 5$, $\beta=1$ and $K_i \sim 2.7 \pm 0.4 \mu\text{M}$). According to this model, (–)-zuonin A binds JNK and weakens its affinity for c-Jun by approximately five-fold ($\alpha \sim 5$) without affecting k_{cat} ($\beta=1$). It is reasonable to propose that (+)-zuonin A follows a similar mechanism, but only marginally weakens the affinity of JNK for c-Jun ($\alpha \sim 1$), presumably because it adopts a binding mode that does not impede the recognition of c-Jun by the DRS.

(–)-zuonin inhibits the activation of JNK1 by MKK4 and MKK7—JNK is activated by the dual-specificity kinases MKK4 and MKK7, which preferentially phosphorylate on Tyr-185 and Thr-183, respectively (18). These kinases are reported to bind JNK within the DRS in a similar manner to the JIP scaffold and c-Jun protein substrate (41). Thus, (–)-zuonin A is predicted to impede the binding of MKK4 and MKK7 to the inactive form of JNK. Indeed, we discovered that (–)-zuonin A does inhibit the phosphorylation of JNK1 by both kinases. Figure 3a shows a dose-response curve for the phosphorylation of JNK1 by MKK4 or MKK7 where the concentration of (–)-zuonin A was varied from 0 – 200 μ M. These reveal values of IC₅₀ similar to those obtained with the active JNKs and furthermore a sub-maximal level of inhibition is observed at saturating (–)-zuonin A, suggestive again of a partial-competitive inhibition mechanism.

Cellular studies

Inhibition of JNK Activation—The effect of both enantiomers of zuonin A on the activation of JNK, or on the phosphorylation of c-Jun, following cell stimulation by anisomycin (which activates the JNK pathway) was assessed in HEK293 cells by western blot analysis. Assessment of the phosphorylation of c-Jun, an *in vivo* substrate of the JNKs (42), as determined using an anti-phospho-Ser-63 antibody, shows it is clearly blunted by the addition of (–)-zuonin A, but not by a DMSO control (Figure 1c). Anisomycin has been reported to induce the appearance of two bands of phosphorylated c-Jun (43). Migration from the lower band to the upper band has been suggested to be due to phosphorylation of Thr-91 and/or Thr-93, in addition to Ser-63 and Ser-73 (43). Interestingly, Figure 1c also shows that (–)-zuonin A blunts the activation of the JNK isoforms in cells in a dose-dependent manner. It should be noted that the phospho JNK antibody used in this study does not distinguish between the JNK isoforms. (–)-zuonin A inhibits JNK activation to a greater extent than it inhibits c-Jun phosphorylation, reflecting the likelihood that complete c-Jun phosphorylation is achieved upon activation of only a fraction of cellular JNK. Figure 1d

shows that (+)-zuonin A inhibits neither JNK activation nor c-Jun phosphorylation, consistent with its decreased ability to inhibit the JNKs in the kinase assays (Figure 1a and 1b).

Investigating JNK self-activation—(–)-Zuonin A does not inhibit JNK2 auto-activation

– The JNK2 isoforms exhibit an ability to self-phosphorylate on the same residues phosphorylated by MKK4 and MKK7 both *in vitro* and in cells, leading to their activation (19). Figure 3b shows that when overexpressed in HEK293T cells JNK2α2 becomes phosphorylated. As it is not known whether the DRS of JNK2α2 is important for autophosphorylation we incubated cells with (–)-zuonin A and assessed the phosphorylation status of the over-expressed JNK2α2 by Western blot analysis. We found that (–)-zuonin A is unable to inhibit JNK2α2 autophosphorylation even at a concentration of 100 μM. In contrast, the phosphorylation of c-Jun, which is mediated by the over-expressed JNK2α2 is clearly blunted upon treatment of the cells with (–)-zuonin A with an ED₅₀ of approximately 25 μM (Figure 3b). This provides strong evidence that (–)-zuonin A binds JNK2α2 in cells and impedes the interaction between JNK2α2 and c-Jun, but does not prevent constitutive JNK2α2 phosphorylation resulting from the kinase binding ATP and phosphorylating itself. When the cells were treated with SP600125 (44) an inhibitor of JNK that binds within the ATP binding pocket of JNK2α2 its autophosphorylation was inhibited. However, when the cells were stimulated using anisomycin SP600125 was no longer able to inhibit JNK2α2 phosphorylation, presumably because it was mediated by the activated MKK4 and MKK7 kinases (Figure 3c). These observations are consistent with the proposed mechanisms of each inhibitor. Whereas (–)-zuonin A inhibits the binding of JNK2α2 to the upstream kinases and downstream substrates it fails to prevent JNK2 from phosphorylating itself. In contrast, SP600125 prevents both JNK2α2 autophosphorylation and substrate phosphorylation, but does not inhibit the ability of MKK4 and MKK7 to phosphorylate JNK2α2.

As noted above, (–)-zuonin A also impedes the phosphorylation of JNKs in cells following stimulation by anisomycin (Figure 1c). While the ability of (–)-zuonin A to inhibit JNK phosphorylation in HEK293 cells might stem from its ability to impede the docking of MKK4 and MKK7 to JNK, it is also possible that other JNK-protein interactions are important. It is notable that the ED₅₀ for inhibiting JNK phosphorylation is around 25 μM, roughly one order of magnitude higher than the IC₅₀ value obtained in the kinase assays. Bioavailability may decrease the cellular potency of (–)-zuonin A compared to the *in vitro* kinase assay. It should be noted, that the typical ED₅₀ for an ATP-competitive kinase inhibitor is in the μM range, reflecting the high concentration of competing MgATP in cells. For example SP600125 is an ATP-competitive inhibitor of JNK with an *in-vitro* cell-free IC₅₀ of ~ 40-100 nM while its ED₅₀ for JNK activity in Jurkat T cells is ~ 10 μM (44). In this regard (–)-zuonin A may be regarded as a useful starting point for the development of more potent analogs. We conclude that (–)-zuonin A inhibits JNK by a protein-competitive mechanism where the competing protein is a JNK substrate, an upstream kinase or a scaffold. It remains to be determined how (–)-zuonin A affects the binding of other proteins, such as other substrates or the MAPK-specific phosphatases that dephosphorylate JNKs.

Inhibition of AKT activation—JNK2 α 2 is reported to promote the tumorigenicity of human glioblastoma cells through Akt, whose activation is dependent on the presence of constitutively active JNK2 in U87MG cells (12, 45). Accordingly, we tested the effect of (–)-zuonin A and a DMSO control on Akt activation in HEK293T cells by monitoring Akt phosphorylation at Ser-473 (46). HEK293T cells were transfected with *WT*-JNK2 α 2 and treated with a DMSO control or different concentrations of (–)-zuonin A without induction by anisomycin. Interestingly, (–)-zuonin A was able to inhibit Akt phosphorylation mediated by JNK2 α 2 (Figure 3d). Thus, (–)-zuonin A has potential as a modulator of Akt activity resulting from constitutive JNK2 α 2 activity.

Selectivity of (–)-zuonin A against other MAPKs in cells—To profile the selectivity of (–)-zuonin A we examined its ability to inhibit other MAP kinases, including ERK1, ERK2, p38MAPK α , p38MAPK β , p38MAPK γ and p38MAPK δ in kinase assays. (–)-zuonin A showed little ability to inhibit any of these MAP kinases, supporting the notion that (–)-zuonin A is selective for the JNKs (Table 1). This was further verified in HEK293T cells. For the p38 MAPK pathway, neither the phosphorylation of p38MAPK α nor ATF2 (Activating Transcription Factor 2), a transcription factor substrate for the p38 MAP kinase, was affected after treatment of cells with 100 μ M (–)-zuonin A (Figure 3f). Similarly, 100 μ M (–)-zuonin A had no effect on the phosphorylation of ERK or its protein substrate p-90RSK (Figure 3e).

Chemical genetics: Altering JNK sensitivity to (–)-zuonin A

In vitro studies—A binding mode for the binding of (–)-zuonin A to JNK was predicted using molecular dynamic simulation (Figure 4a). The benzodioxole groups on (–)-zuonin A can potentially interact with both charged and non-polar residues on JNK. The modeling suggests that one benzodioxole group may engage in π -stacking interactions with Tyr-130 and Trp-324 of JNK, with the other ring binding in the region of Asp-126, Arg-127, Cys-163 and Thr-164. We were interested in verifying the binding site of (–)-zuonin A and also wanted to identify residues whose mutation might compromise its binding. Accordingly, the following mutations, R127A, Y130A, C163A, T164A, W324A and D326A were incorporated individually into JNK2 α 2. Initially, we tested whether any of mutants exhibited altered kinetic parameters using c-Jun as the protein substrate. Only the R127A mutant of JNK2 α 2 exhibited altered kinetic parameters for c-Jun phosphorylation, with the mutation resulting in an increase in the K_m for c-Jun of 15-fold (Table 2). As shown in Figure 4b and Table 2, the C163A, R127A and T164A mutants all exhibited an increased IC_{50} providing some support for the binding model. Interestingly, these mutations all resulted in a two-fold decrease in the observed level of maximal inhibition at a saturating (–)-zuonin A. In contrast, the Y130A and W324A mutants not only retained their ability to bind (–)-zuonin A but also displayed a shift in mechanism from partial to full inhibition (Table 2). Thus, mutation of Tyr-130 or Trp-324 to alanine results in a mutant that phosphorylates c-Jun normally, but is significantly more sensitive to (–)-zuonin A than wild type JNK2.

Cellular studies—The C163A and Y130A mutants exhibited similar abilities to phosphorylate c-Jun, yet markedly different sensitivities to (–)-zuonin A, suggesting that they could be used in chemical genetic studies (47) to elucidate the role of JNK2 in cells.

JNK2 α 2 (C163A) and JNK2 α 2 (Y130A) were transfected into HEK293T cells, which were subsequently treated with varied concentrations of (–)-zuonin A. Autophosphorylation of JNK2 α 2 and the subsequent phosphorylation of c-Jun were examined and compared to cells that were not transfected. The extent of phosphorylation of the JNK2 mutants was similar to exogenously expressed WT JNK2 α 2 in the absence of (–)-zuonin A (compare Figure 3b and 4c). As expected, autophosphorylation of transfected and endogenous JNK was unaffected by (–)-zuonin A treatment (Figure 4c). However, a significant difference in the dose-dependence of c-Jun phosphorylation is evident between cells transfected with JNK2 α 2 (Y130A) and those transfected with JNK2 α 2 (C163A). Cells transfected with JNK2 α 2 Y130A are more sensitive to (–)-zuonin A than those transfected either with WT JNK2 α 2 or those not transfected at all. Strikingly, cells transfected with JNK2 α 2 (C163A) are unresponsive to (–)-zuonin A. (Figures 3b and 4c). While further studies are required to determine whether these mutations affect interactions between JNK and other proteins (e.g. other substrates) they hold promise as chemical-genetic tools to examine the function of JNK2 in cells.

(–)-zuonin A impedes migration of breast cancer cells

The invasion-metastatic cascade involves a series of events whereby tumor cells leave the primary tumor, intravasate into the circulation, extravasate at distant tissues, and establish micrometastases that may grow into macroscopic secondary tumors (48). Cell migration is an early requirement for tumor metastasis, so inhibition of cell migration provides a potential strategy to inhibit metastasis (49). The JNK pathway is known to play important roles in cell migration (e.g. (50)) and previously, we demonstrated an ability of a peptide that is selective for JNK2 to inhibit breast cancer cell migration (16). Therefore, we examined whether (–)-zuonin A or (+)-zuonin A inhibited chemotactic cell migration of a highly metastatic human breast cancer cell line, namely MDA-MB-231 in a transwell assay. MDA-MB-231 cells were treated with DMSO, (–)-zuonin A (50 μ M and 100 μ M) or (+)-zuonin A (50 and 100 μ M) (Figure 5) overnight. Cell viability was monitored during the migration assay and found to be unaffected by the addition of the compounds. Untreated MDA-MB-231 cells showed robust migration in response to serum, while cells treated with 50 and 100 μ M (–)-zuonin A exhibited approximately 45% and 80% inhibition of migration, respectively (Figure 5a). Although (+)-zuonin A was able to mildly suppress cell migration, there is a clear difference between the ability of the two isomers in this respect (Figure 5b), supporting the notion that JNK2 signaling contributes to breast cancer cell migration. Since cells also use their migration machinery during wound closure a scratch wound closure assay was used to examine the effect of zuonin A on the ability of MDA-MB-231 cells to repair wounds. Wound assays were performed to measure the influence of 25–100 μ M of (–)-zuonin A and (+)-zuonin A on cell migration to close a scratch wound over time. Cell viability was monitored during the wound assay and found to be unaffected by the addition of the compounds up to 200 μ M. Both 100 and 200 μ M (–)-zuonin A was sufficient to inhibit wound closure in MDA MB 231 cells (Figure 5c). Like the chemotaxis based transwell migration assay, (–)-zuonin A showed notable potency to inhibit wound closure in comparison to (+)-zuonin A. These data are consistent with the observed potency of the two isomers towards JNK in both cell-free (Table 1) and cell-based *in vitro* assays (Figure 1 &

5d). However, the possibility of additional affects of (–)-zuonin A on cell migration, which are not attributable to JNK2 cannot be ruled out.

To summarize, we report the asymmetric synthesis of the lignans (–)-zuonin A and (+)-zuonin A and established the absolute configuration of the natural products. We show that (–)-zuonin A is a selective inhibitor of the JNKs and identify two mechanisms as likely contributors to its ability to inhibit JNK signaling in cells; *i*) (–)-zuonin A inhibits JNK activation by MKK4 and MKK7 and *ii*) it inhibits substrate phosphorylation. In both cases it impedes the binding of the corresponding protein to the D-recruitment site of JNK. While (+)-zuonin A binds JNK, it is not an effective inhibitor. The activity of (–)-zuonin towards JNK is the basis for its ability to inhibit Akt signaling and breast cancer cell migration. Mutations in the predicted binding site for (–)-zuonin A can render it significantly more, or less sensitive to inhibition than wild type JNK2, allowing for the design of potential chemical genetic experiments. These studies suggest that the biological activity reported for other lignans, such as saucerneol F and zuonin B may be the result of blocking protein-protein interactions within MAPK cascades. These discoveries hold the potential to introduce future analogs into the arsenal of therapeutics now used to fight cancer cell metastasis.

Methods

Cell culture, Western blot analysis and Cell migration assays are described in detail in the supporting information.

Kinase activity assay

MAP kinase assays were conducted as described in the supporting information.

Expression, Purification and Activation of Tagless MAP Kinases, GST-ATF2 (1-115), GST-C-Jun (1-221) and His-Ets-1 (1-138)

Different MAP kinases and protein substrates were expressed, purified then activated (if required) according to the methods described in the supporting information.

The molecular dynamics simulations

Molecular dynamics simulations for (–)-zuonin A bound to JNK are described in the supporting information.

Data Analysis

Steady-state kinetic experiments - Reactions were carried out as mentioned in the kinase activity assay except in the kinetic mechanism study, where we varied concentrations of substrate (c-Jun) and (–)-zuonin A. Initial rates were determined by linear least squares fitting to plots of product against time. Reciprocal plots of $1/v$ against $1/s$ were checked for linearity, before the data were fitted to Equation 1 using a non-linear least squares approach, assuming equal variance for velocities, using the program Kaleidagraph 3.5 (Synergy software). Values for kinetic constants were then obtained using the program Sigma plot by fitting the kinetic data to the relevant over-all equation. Data conforming to linear

competitive inhibition were fitted to Equation 2; data conforming to hyperbolic mixed inhibition were fitted to Equation 3, which corresponds to an equation for partial competitive inhibition. Dose-response curves for data conforming to inhibition were fitted to Equation 4.

$$\frac{V_0}{V_{\max}^{\text{app}}} = \frac{s}{K_{\text{mS}}^{\text{app}} + s} \quad \text{Equation 1}$$

$$\frac{V_0}{V_{\max}^{\text{app}}} = \frac{s}{K_{\text{mS}}^{\text{app}}(1 + i/K_{\text{ic}}^{\text{app}}) + s} \quad \text{Equation 2}$$

$$\frac{V_0}{V_{\max}^{\text{app}}} = \frac{s}{K_{\text{mS}}^{\text{app}} \left(\frac{1 + \frac{i}{K_{\text{i}}^{\text{app}}}}{1 + \frac{\beta i}{\alpha K_{\text{i}}^{\text{app}}}} \right) + s \left(\frac{1 + \frac{i}{\alpha K_{\text{i}}^{\text{app}}}}{1 + \frac{\beta i}{\alpha K_{\text{i}}^{\text{app}}}} \right)} \quad \text{Equation 3}$$

$$V_0 = V_{00} - \left(V_{00} \frac{i}{i + (K_{50})} \right) + V' \quad \text{Equation 4}$$

The parameters used in deriving equations are defined as follows; V_0 , observed rate; $V_{\max}^{\text{app}}$, apparent maximum rate; s , concentration of substrate S; $K_{\text{mS}}^{\text{app}}$, apparent Michaelis constant for substrate S; i , concentration of inhibitor I ; $K_{\text{i}}^{\text{app}}$ or $K_{\text{ic}}^{\text{app}}$, apparent competitive inhibition constant for inhibitor I ; $\alpha K_{\text{i}}^{\text{app}}$, apparent uncompetitive inhibition constant for inhibitor I ; $\beta V_{\max}^{\text{app}}$, apparent maximum rate for enzyme inhibitor complex; V_{00} , is the observed rate in the absence of inhibitor, V' is the observed rate constant at saturating inhibitor, I , or activator x , K_{50} is the concentration that leads to half the maximal change in V_0 .

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support was from grants from the National Institute of General Medical Sciences (R01GM059802), the Welch Foundation (F-1390), and Texas Institute for Drug & Diagnostic Development (H-F-0032) to K.N.D. Financial support for the computational studies was from the National Institute of General Medical Sciences (R01GM079686) to PR. The authors gratefully acknowledge supercomputer time provided the Texas Advanced Computing Center (TACC) and TeraGrid (MCB100057) at the University of Texas at Austin. TSK acknowledges The University of Texas at Austin for The A.D. Hutchinson Student Endowment Fellowship. JH is grateful to Duke

University for funding this work, to the North Carolina Biotechnology Center (NCBC) (Grant No. 2008-IDG-1010) for funding of NMR instrumentation, and to the National Science Foundation (NSF) MRI Program (Award ID No. 0923097) for funding mass spectrometry instrumentation. The Authors thank G. Mills for providing the cell lines and reagents for the migration assays and providing laboratory space and advice to SM, E. Anslyn for providing laboratory space and advice to JJ, P. LoGrasso for providing JNK plasmids and A. Syrett for preparing the TOC figure. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health

References

1. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ. 1996; Selective interaction of JNK protein kinase isoforms with transcription factors. *EMBO J.* 15:2760–2770. [PubMed: 8654373]
2. Davis RJ. 2000; Signal transduction by the JNK group of MAP kinases. *Cell.* 103:239–252. [PubMed: 11057897]
3. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. *Biochim Biophys Acta.* 1804:463–475.
4. Manning AM, Davis RJ. 2003; Targeting JNK for therapeutic benefit: from junk to gold? *Nat Rev Drug Discov.* 2:554–565. [PubMed: 12815381]
5. Huang P, Han J, Hui L. 2010; MAPK signaling in inflammation-associated cancer development. *Protein Cell.* 1:218–226. [PubMed: 21203968]
6. Chen F, Castranova V. 2009; Beyond apoptosis of JNK1 in liver cancer. *Cell Cycle.* 8:1145–1147. [PubMed: 19270500]
7. Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B, Behrens A. 2009; JNK signalling modulates intestinal homeostasis and tumorigenesis in mice. *EMBO J.* 28:1843–1854. [PubMed: 19521338]
8. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. 2007; Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. *Cancer Cell.* 11:555–569. [PubMed: 17560336]
9. She QB, Chen N, Bode AM, Flavell RA, Dong Z. 2002; Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. *Cancer Res.* 62:1343–1348. [PubMed: 11888903]
10. Tong C, Yin Z, Song Z, Dockendorff A, Huang C, Mariadason J, Flavell RA, Davis RJ, Augenlicht LH, Yang W. 2007; c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. *Am J Pathol.* 171:297–303. [PubMed: 17591974]
11. Tsuiji H, Tnani M, Okamoto I, Kenyon LC, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Wong AJ. 2003; Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. *Cancer Res.* 63:250–255. [PubMed: 12517805]
12. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, Tnani M, Holgado-Madruga M, Moscatello DK, Wong AJ. 2002; Elevated JNK activation contributes to the pathogenesis of human brain tumors. *Oncogene.* 21:5038–5046. [PubMed: 12140754]
13. Weston CR, Davis RJ. 2007; The JNK signal transduction pathway. *Curr Opin Cell Biol.* 19:142–149. [PubMed: 17303404]
14. Mitra S, Lee JS, Cantrell M, Van den Berg CL. 2011; c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). *J Biol Chem.* 286:15287–15297. [PubMed: 21357683]
15. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. 2003; Cell migration: integrating signals from front to back. *Science.* 302:1704–1709. [PubMed: 14657486]
16. Kaoud TS, Mitra S, Lee S, Taliaferro J, Cantrell M, Linse KD, Van Den Berg CL, Dalby KN. 2011; Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. *ACS chemical biology.* 6:658–666. [PubMed: 21438496]
17. Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, Laughlin JD, Park H, LoGrasso PV, Patricelli M, Nomanbhoy TK, Sorger PK, Alessi DR,

- Gray NS. 2012; Discovery of potent and selective covalent inhibitors of JNK. *Chem Biol.* 19:140–154. [PubMed: 22284361]
18. Fleming Y, Armstrong CG, Morrice N, Paterson A, Goedert M, Cohen P. 2000; Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. *Biochem J.* 352 Pt 1:145–154. [PubMed: 11062067]
19. Nitta RT, Chu AH, Wong AJ. 2008; Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. *J Biol Chem.* 283:34935–34945. [PubMed: 18940813]
20. Yasuda J, Whitmarsh AJ, Cavanagh J, Sharma M, Davis RJ. 1999; The JIP group of mitogen-activated protein kinase scaffold proteins. *Mol Cell Biol.* 19:7245–7254. [PubMed: 10490659]
21. Zhan X, Kaoud TS, Dalby KN, Gurevich VV. 2011; Nonvisual arrestins function as simple scaffolds assembling the MKK4-JNK3alpha2 signaling complex. *Biochemistry.* 50:10520–10529. [PubMed: 22047447]
22. Schnieders MJ, Kaoud TS, Yan C, Dalby KN, Ren P. 2012; Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases. *Current pharmaceutical design.* 18:1173–1185. [PubMed: 22316156]
23. Stebbins, JL; De, SK; Machleidt, T; Becattini, B; Vazquez, J; Kuntzen, C; Chen, LH; Cellitti, JF; Riel-Mehan, M; Emdadi, A; Solinas, G; Karin, M; Pellecchia, M. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. *Proceedings of the National Academy of Sciences of the United States of America*; 2008. 16809–16813.
24. Chambers JW, Cherry L, Laughlin JD, Figueroa-Losada M, Lograsso PV. 2011; Selective Inhibition of Mitochondrial JNK Signaling Achieved Using Peptide Mimicry of the Sab Kinase Interacting Motif-1 (KIM1). *ACS Chemical Biology.* 6:808–818. [PubMed: 21563797]
25. Johnson LN. 2009; Protein kinase inhibitors: Contributions from structure to clinical compounds. *Quarterly reviews of biophysics.* 42:1–40. [PubMed: 19296866]
26. Kaoud TS, Yan C, Mitra S, Tseng CC, Jose J, Tuohetahuntala MH, H P, Shi Y, Hong J, Ren P, Dalby KN. 2012 From in Silico Discovery to intra-Cellular Activity: Targeting the JNK-JIP Protein-Protein Interaction with Small Molecules.
27. Urzua A, Freyer AJ, Shamma M. 1987; 2,5-Diaryl-3,4-dimethyltetrahydrofuranoid lignans. *Phytochemistry.* 26:1509–1511.
28. Rao KV, Rao NS. 1990; Chemistry of *Saururus cernuus*, VI: Three new neolignans. *Journal of natural products.* 53:212–215. [PubMed: 2161446]
29. Tyagi OD, Jensen S, Boll PM, Sharma NK, Bisht KS, Parmar VS. 1993; Lignans and neolignans from *Piper schmidtii*. *Phytochemistry.* 32:445–448.
30. Kuo YH, Chen CH, Lin YL. 2002; New lignans from the heartwood of *Chamaecyparis obtusa* var. *formosana*. *Chemical & Pharmaceutical Bulletin.* 50:978–980. [PubMed: 12130860]
31. Konishi T, Konoshima T, Daikonya A, Kitanaka S. 2005; Neolignans from *Piper futokadsura* and their inhibition of nitric oxide production. *Chem Pharm Bull (Tokyo).* 53:121–124. [PubMed: 15635246]
32. Lu Y, Suh SJ, Kwak CH, Kwon KM, Seo CS, Li Y, Jin Y, Li X, Hwang SL, Kwon O, Chang YC, Park YG, Park SS, Son JK, Kim CH, Chang HW. 2012; Saucerneol F, a new lignan, inhibits iNOS expression via MAPKs, NF-kappaB and AP-1 inactivation in LPS-induced RAW264.7 cells. *Int Immunopharmacol.* 12:175–181. [PubMed: 22155103]
33. 2012; Zuonin B Inhibits Lipopolysaccharide-Induced Inflammation via Downregulation of the ERK1/2 and JNK Pathways in RAW264.7 Macrophages. *Evidence-Based Complementary and Alternative Medicine.* 2012
34. Kim H, Wooten CM, Park Y, Hong J. 2007; Stereoselective synthesis of tetrahydrofuran lignans via BF(3) × OEt(2)-promoted reductive deoxygenation/epimerization of cyclic hemiketal: synthesis of (-)-odoratisol C, (-)-futokadsurin A, (-)-veraguensin, (+)-fragransin A(2), (+)-galbelgin, and (+)-talaumidin. *Org Lett.* 9:3965–3968. [PubMed: 17764190]
35. Kim H, Kasper AC, Moon EJ, Park Y, Wooten CM, Dewhirst MW, Hong J. 2009; Nucleophilic addition of organozinc reagents to 2-sulfonyl cyclic ethers: stereoselective synthesis of manassantins A and B. *Org Lett.* 11:89–92. [PubMed: 19111058]

36. Evans DA, Bartroli J, Shih TLJ. 1981; Enantioselective aldol condensations. 2. Erythro-selective chiral aldol condensations via boron enolates. *J Am Chem Soc.* 103:2127–2129.
37. Schreiber J, Maag H, Hashimoto N, Eschenmoser A. 1971; Dimethyl(methylene)ammonium iodide. *Angew Chem Int Ed Engl.* 10:330–331.
38. Mandal M, Yun H, Dudley GB, Lin S, Tan DS, Danishefsky SJ. 2005; Total synthesis of guanacastepene a: a route to enantiomeric control. *J Org Chem.* 70:10619–10637. [PubMed: 16355979]
39. Abramczyk O, Rainey MA, Barnes R, Martin L, Dalby KN. 2007; Expanding the repertoire of an ERK2 recruitment site: cysteine footprinting identifies the D-recruitment site as a mediator of Ets-1 binding. *Biochemistry.* 46:9174–9186. [PubMed: 17658891]
40. Niu L, Chang KC, Wilson S, Tran P, Zuo F, Swinney DC. 2007; Kinetic characterization of human JNK2 α 2 reaction mechanism using substrate competitive inhibitors. *Biochemistry.* 46:4775–4784. [PubMed: 17397142]
41. Bardwell AJ, Frankson E, Bardwell L. 2009; Selectivity of docking sites in MAPK kinases. *J Biol Chem.* 284:13165–13173. [PubMed: 19196711]
42. Repici M, Mare L, Colombo A, Ploia C, Sclip A, Bonny C, Nicod P, Salmona M, Borsello T. 2009; c-Jun N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons. *Neuroscience.* 159:94–103. [PubMed: 19135136]
43. Clerk A, Sugden PH. 1997; Cell stress-induced phosphorylation of ATF2 and c-Jun transcription factors in rat ventricular myocytes. *Biochem J.* 325(Pt 3):801–810. [PubMed: 9271103]
44. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001; SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. *Proc Natl Acad Sci U S A.* 98:13681–13686. [PubMed: 11717429]
45. Cui J, Han SY, Wang C, Su W, Harshyne L, Holgado-Madruga M, Wong AJ. 2006; c-Jun NH(2)-terminal kinase 2 α 2 promotes the tumorigenicity of human glioblastoma cells. *Cancer Res.* 66:10024–10031. [PubMed: 17047065]
46. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. 1996; Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* 15:6541–6551. [PubMed: 8978681]
47. Kawasumi M, Nghiem P. 2007; Chemical genetics: elucidating biological systems with small-molecule compounds. *J Invest Dermatol.* 127:1577–1584. [PubMed: 17568801]
48. Bacac M, Stamenkovic I. 2008; Metastatic cancer cell. *Annu Rev Pathol.* 3:221–247. [PubMed: 18233952]
49. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. 2009; A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell.* 137:1032–1046. [PubMed: 19524507]
50. Huang C, Jacobson K, Schaller MD. 2004; A role for JNK-paxillin signaling in cell migration. *Cell Cycle.* 3:4–6. [PubMed: 14657652]
51. Heo JS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, Lee JI, Park SY, Kim JH, Hwang KY, Hyun YL, Jeon YH, Ro S, Cho JM, Lee TG, Yang CH. 2004; Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. *Embo J.* 23:2185–2195. [PubMed: 15141161]

Figure 1. (–)-zuonin A, but not (+)-zuonin A is a potent JNK inhibitor in *in vitro* cell-free and cell-based kinase assays

(a) The effect of (–)-zuonin A on the ability of JNK1, JNK2 and JNK3 to phosphorylate GST-c-Jun (1-221). Data were fitted to Equation 4. **(b)** The effect of (+)-zuonin A on the ability of JNK1, JNK2 and JNK3 to phosphorylate GST-c-Jun (1-221). Data were fitted to Equation 4. **(c)** HEK293 cells were treated with a DMSO control or (–)-zuonin A (5-100 μM) for 12 hours. The JNK pathway was then induced by the addition of anisomycin (50-100 nM) for 5-10 minutes before lysing the cells. Lysates were fractionated by SDS PAGE (10 % gel) and subjected to western blot analysis in order to detect the phosphorylated forms of c-Jun and JNK. A graphical analysis is shown, representative of three independent experiments. **(d)** As in Figure 1d using (+)-zuonin A.

Figure 2. Mechanism of JNK inhibition by (-)-zuonin A

(a) Double reciprocal plot of $1/V_0$ vs $1/[c-Jun]$ at varied fixed concentrations of (-)-zuonin A (0-50 μM) and 0.5 mM MgATP. Initial velocities were measured using various (0.63-20 μM) concentrations of c-Jun. The data were fitted to a model of partial competitive inhibition according to Equation 3, where $k_{cat}^{app} = 1.2 \pm 0.08 s^{-1}$, $K_m^{app} = 1.6 \pm 0.03 \mu M$, $K_i^{app} = 2.7 \pm 0.4 \mu M$, $\alpha K_m^{app} = 8 \pm 0.2$, $\alpha = 5 \pm 0.3$ and $\beta = 1$. **(b)** Proposed mechanisms of partial competitive C-Jun inhibition by (-)-zuonin A.

Figure 3. Mechanism of JNK inhibition by (-)-zuonin A in HEK293T cells

(a) The effect of (-)-zuonin A on the ability of active MKK7 (WT) and active MKK4 (WT) to phosphorylate inactive JNK1 with $\text{IC}_{50} \sim 2.0 \pm 0.15$ and $1.8 \pm 0.17 \mu\text{M}$, respectively. Data were fitted to Equation 4. (b) HEK293T cells were transfected with *WT*-JNK2 and treated with a DMSO control or different concentrations of (-)-zuonin A without induction by anisomycin. A graphical analysis is shown in Figure 4d. (c) HEK293T cells were transfected with *WT*-JNK2 and treated with a DMSO control or two concentrations of SP600125 (ATP-competitive JNK inhibitor) with and without induction by anisomycin. (d) HEK293T cells were transfected either with empty pcDNA3 vector or with *WT*-JNK2 and treated with a DMSO control or different concentrations of (-)-zuonin A without induction by anisomycin. (-)-zuonin A did not inhibit AKT expression but inhibited AKT phosphorylation. (e) Specificity of (-)-zuonin A towards ERK2 in HEK293 cells. Cells were treated a DMSO control or with (-)-zuonin A (0-100 μM) for 12 hours. The ERK2 pathway was then induced by 50 ng EGF (Epidermal Growth Factor) for 5-10 minutes before lysing the cells. Lysates were fractionated by SDS PAGE (10% gel) and subjected to Western blot analysis in order to detect the phosphorylated forms of ERK and p90RSK (p90 Ribosomal S6 Kinase). (f) Specificity of (-)-zuonin A towards p38 MAPKs in HEK293 cells. Cells were treated with a DMSO control or (-)-zuonin A (10-100 μM) for 12 hours. The p38 pathway was induced by the addition of anisomycin (50-100 nM) for 5-10 minutes before lysing the cells. Lysates were fractionated by SDS PAGE (10% gel) and subjected to Western blot analysis in order to detect the phosphorylated forms of p38, and ATF2.

Figure 4. Altering JNK sensitivity to (-)-zuonin A

(a) The MD trajectories for (-)-zuonin A binding to JNK1 (PDB ID: 1UKH) (51). The figure was generated using PyMol software (<http://pymol.sourceforge.net/>). (b) The effect of different JNK2 DRS site mutations on the sensitivity of JNK2 towards (-)-zuonin A, detected by measuring the ability of each mutant to phosphorylate GST-c-Jun (1-221) in the presence of (-)-zuonin A. Data were fitted to equation 4. (c) HEK293 cells were transfected with empty pcDNA 3 vector, JNK2 (Y130A) or JNK2 (C163) and treated with different concentrations of (-)-zuonin A (0–100 μM). Subsequent phosphorylation of JNK and c-Jun was detected by western blot. (d) Graphical analysis for The effect of different JNK2 DRS site mutations on the sensitivity of JNK2 towards (-)-zuonin A in HEK293T cells, representative of three independent experiments. Lysates were fractionated by SDS PAGE (10 % gel) and subjected to western blot analysis in order to detect the phosphorylated forms of c-Jun and JNK.

Figure 5. (-)-zuonin A inhibits MDA MB 231 breast cancer cell migration more than (+)-zuonin A

(a) Representative images of migrated cells on the underside of a transwell membrane stained with crystal violet dye. 50–100 μ M of (-)-zuonin A significantly reduces the number of cells that travel through the transwell pores to successfully reach the underside of the transwell membrane (migrated cells) in comparison to the untreated cells. (b) (-)-zuonin A inhibits MDA MB 231 breast cancer cell migration more than (+)-zuonin A at 100 μ M. This experiment has been independently repeated three times. (c) Wound healing assay, after treatment of MDA MB 231 breast cancer cell with different concentrations of (-)-zuonin and (+)-zuonin A, a scratch wound was created in each sample, and culture media were replaced with 1% FBS-containing media. Wound closure was measured at time 0 and at 24 hrs post-wounding. Graphical analysis representative of three independent experiments. (d) MDA MB 231 cells were treated with a DMSO control or (-)-zuonin A (10 – 200 μ M) for 12 hours before lysing the cells. Lysates were fractionated by SDS PAGE (10 % gel) and subjected to western blot analysis in order to detect the phosphorylated forms of c-Jun and JNK.

Scheme 1.

Asymmetric synthesis of (-)-zuonin A.^a

^aReagents and conditions: (a) *n*-Bu₂BOTf, Et₃N, CH₂Cl₂, -78 °C, 30 min, then piperonal, -78 °C, 1 h, 78%; (b) TBSCl, imidazole, DMF, 25 °C, 14 h, 90%; (c) LiBH₄, MeOH, Et₂O, 0 °C, 1 h, 79%; (d) MsCl, Et₃N, CH₂Cl₂, -78 °C, 30 min; (e) NaCN, DMSO, 70 °C, 2 h, 97% for 2 steps; (f) TBAF, THF, 25 °C, 1 h; (g) NaOH, THF/MeOH/H₂O (1:1:1), reflux, 16 h; (h) PPTS, toluene, 80 °C, 2 h, 91% for 3 steps; (i) LiHMDS, THF, -78 °C, 30 min, then Eschenmoser's salt, -78 °C, 15 min; (j) *m*-CPBA, NaHCO₃, THF, 25 °C, 30 min, 95% for 2 steps; (k) DIBALH, CH₂Cl₂, -78 °C, 10 min, 87%; (l) PhSO₂H, CaCl₂, CH₂Cl₂, 25 °C, 10 min, 66%; (m) **11**, ZnBr₂, THF, 25 °C, 30 min, 76%; (n) Pd/C, H₂, EtOAc/MeOH (3:1), 25 °C, 1 h, 38%, dr = 5:1.

Table 1

Selectivity of (–)-zuonin A.

Kinase	IC ₅₀ (μM) ^a	% Inhibition at Saturating (–)-zuonin A (200 μM)
JNK1	1.7±0.26	75%
JNK2	2.9±0.17	70%
JNK3	1.74±0.16	73%
WT-MKK4 ^a	1.8±0.17	77%
WT-MKK7 ^a	1.99±0.15	50%
ERK1	>200	10%
ERK2	>200	10%
p38MAPKα	>200	20%
p38MAPKβ	No inhibition	15%
p38MAPKγ	>200	10%
p38MAPKδ	>200	10%

^aInhibits the phosphorylation of JNK.

Table 2

Effect of JNK2 Mutations on the Sensitivity of JNK towards (–)-zuonin A.

Mutants	K_m μM	k_{cat} s^{-1}	k_{cat}/K_m $\mu\text{M}^{-1} \text{s}^{-1}$	IC_{50} μM	% Inhibition at 200 μM
JNK2 WT	1.65±0.1	1±0.15	0.6	2.9±0.17	70%
JNK2 (R127A)	23.6±1.1	1.4±0.3	0.06	14±2.1	80%
JNK2 (Y130A)	1.87±0.3	1±0.04	0.53	2.3±0.16	95%
JNK2 (C163A)	1.33±0.4	1±0.065	0.75	37±2.5	37%
JNK2 (T164A)	0.73±0.18	1.1±0.064	1.5	13.6±1.5	39%
JNK2 (W324A)	2.3±0.15	1.06±0.075	0.46	16.6±0.17	98%
JNK2 (D326A)	2±0.83	0.8±0.08	0.4	2.8±0.32	71%

^a IC_{50} Determined as described in Methods section, Data were fitted to equation 4^b Initial velocity data at different concentrations of c-Jun were fitted to equation 1